Emilio Vargas Castrillón-rekin lankidetzan egindako argitalpenak (10)

2021

  1. Meta-Analysis of Reversal Agents for Severe Bleeding Associated With Direct Oral Anticoagulants

    Journal of the American College of Cardiology, Vol. 77, Núm. 24, pp. 2987-3001

  2. Reply: Preventing Bleeding With Direct-Acting Oral Anticoagulants

    Journal of the American College of Cardiology

2018

  1. Causes of Death in Patients with Venous Thromboembolism Anticoagulated with Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis

    Seminars in Thrombosis and Hemostasis, Vol. 44, Núm. 4, pp. 377-387

2015

  1. Case Fatality Rates of Recurrent Thromboembolism and Bleeding in Patients Receiving Direct Oral Anticoagulants for the Initial and Extended Treatment of Venous Thromboembolism

    Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 20, Núm. 5, pp. 490-500

  2. Direct-acting oral anticoagulants: Pharmacology, indications, management, and future perspectives

    European Journal of Haematology, Vol. 95, Núm. 5, pp. 389-404

2014

  1. Direct oral anticoagulants in the treatment of acute venous thromboembolism: A systematic review and meta-analysis

    Thrombosis Research, Vol. 134, Núm. 4, pp. 774-782

  2. Direct oral anticoagulants in the treatment of venous thromboembolism, with a focus on patients with pulmonary embolism: an evidence-based review

    Vascular health and risk management, Vol. 10, pp. 627-639

  3. Specific antidotes in development for reversal of novel anticoagulants: A review

    Recent Patents on Cardiovascular Drug Discovery, Vol. 9, Núm. 1, pp. 2-10

2013

  1. Potential role of new anticoagulants for prevention and treatment of venous thromboembolism in cancer patients.

    Vascular health and risk management, Vol. 9, pp. 207-228

2011

  1. New parenteral anticoagulants in development

    Therapeutic Advances in Cardiovascular Disease, Vol. 5, Núm. 1, pp. 33-59